Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4192.90 +0.6% SILVER 57.88 +1.3% COPPER 6.64 +1.2% OIL 96.31 −1.7% PALLADIUM 1128.75 +0.0% QZM 0.380 −2.6% BVA 0.760 −3.8% ONAU 0.520 −1.9% FMR 0.225 +0.0% GSVR 0.340 +3.0% PHNM 0.340 −1.4% SLG 5.71 +0.5% CASA 0.060 +0.0% DRY 0.215 −6.5% SOMA 0.560 +1.8% PWRO 0.025 +0.0% OMI 0.250 +2.0% EMR 0.100 −4.8% PDN 7.10 −1.2% FDY 4.79 +0.4% NTR 98.77 −0.7% GOLD 4192.90 +0.6% SILVER 57.88 +1.3% COPPER 6.64 +1.2% OIL 96.31 −1.7% PALLADIUM 1128.75 +0.0% QZM 0.380 −2.6% BVA 0.760 −3.8% ONAU 0.520 −1.9% FMR 0.225 +0.0% GSVR 0.340 +3.0% PHNM 0.340 −1.4% SLG 5.71 +0.5% CASA 0.060 +0.0% DRY 0.215 −6.5% SOMA 0.560 +1.8% PWRO 0.025 +0.0% OMI 0.250 +2.0% EMR 0.100 −4.8% PDN 7.10 −1.2% FDY 4.79 +0.4% NTR 98.77 −0.7%

Healthcare

Page 52
  1. Mar 05, 2026 · 18:15 · ZYUS

    ZYUS Life Sciences Announces Closing of Debt Financing

    ZYUS Life Sciences Announces Closing of Debt Financing

    01
  2. Mar 05, 2026 · 17:48 · HLS

    HLS Therapeutics launches Nilemdo in Canada

    HLS Therapeutics launches Nilemdo in Canada

    02
  3. Mar 05, 2026 · 17:42 · NURS

    Hydreight invests $300,000 in Insu Therapeutics

    Hydreight invests $300,000 in Insu Therapeutics

    03
  4. Mar 05, 2026 · 17:15 · NLH

    President & CEO Letter to Shareholders

    President & CEO Letter to Shareholders

    04
  5. Mar 05, 2026 · 17:13 · NLH

    Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA

    Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA

    05
  6. Mar 05, 2026 · 17:10 · CSCI

    COSCIENS Provides Strategic Update

    COSCIENS Provides Strategic Update

    06
  7. Mar 05, 2026 · 17:00 · HELP

    Cybin talks HLP004 phase 2 study results

    Cybin talks HLP004 phase 2 study results

    07
  8. Mar 05, 2026 · 16:05 · PRN

    Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results

    Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results

    08
  9. Mar 05, 2026 · 15:45 · ADK

    DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

    DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

    09
  10. Mar 05, 2026 · 08:00 · NURS

    Hydreight Technologies Inc. Announces Strategic Investment in Insu Therapeutics to Advance Needle-Free Peptide Delivery Technology

    Hydreight Technologies Inc. Announces Strategic Investment in Insu Therapeutics to Advance Needle-Free Peptide Delivery Technology

    10
  11. Mar 05, 2026 · 07:30 · HELP

    Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

    Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

    11
  12. Mar 05, 2026 · 07:00 · HLS

    HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease

    HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease

    12
  13. Mar 04, 2026 · 19:41 · CRRX

    CareRx Reports 2025 Year-End and Fourth Quarter Results

    CareRx Reports 2025 Year-End and Fourth Quarter Results

    13
  14. Mar 04, 2026 · 18:28 · ASG

    Aurora Spine cuts loan rate, extends insider note

    Aurora Spine cuts loan rate, extends insider note

    14
← Newer Older →